RxDoctor Payments Data

Margaret Gill, CNM

Family · Knoxville, TNNPI 1184979007

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 68 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$399
  • Gilead$387
  • Janssen Products, LP$249
  • Theratechnologies Inc.$58
  • Johnson & Johnson$41
  • Teva Pharmaceuticals USA, Inc.$23
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$96780%
  • Education$24920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,216 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,627
Medicare patients
12
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala201$781,586
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf61$287,064
CabenuvaCabotegravir/Rilpivirine28$186,360
GenvoyaElviteg/Cob/Emtri/Tenof Alafen32$118,065
DescovyEmtricitabine/Tenofov Alafenam38$88,127
TivicayDolutegravir Sodium29$68,861
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$46,173
PrezcobixDarunavir/Cobicistat12$34,371
PifeltroDoravirine12$24,485
JardianceEmpagliflozin17$10,530
InvokanaCanagliflozin13$7,419
Darunavir15$2,530
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,101
Ventolin HfaAlbuterol Sulfate20$1,074
Gabapentin42$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$387$987,778271 claims
Janssen Products, LPSymtuza$249$287,06461 claims
Viiv Healthcare CompanyCabenuva, Tivicay$399$255,22157 claims
Johnson & JohnsonPrezcobix, Invokana$41$41,79025 claims
MerckPifeltro$23$24,48512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →